Related Experiment Video

Updated: Jul 5, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal treatment for low-risk prostate cancer

Aaron E Katz1, Ravi Kacker

  • 1Department of Urology, Columbia University Medical Center, New York, NY 10032, USA. aek4@columbia.edu

BJU International
|May 24, 2008
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Experiment Videos

Last Updated: Jul 5, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Articles linked to this work by shared authors, journal, and citation graph.

Abiraterone Acetate Affects Gene Expression Profile in a Human Male Neuronal Cell Line: Potential Mechanism for Cognitive Deficits with Prostate Cancer Therapy.

Life (Basel, Switzerland)·2026

Differential Cytokine Profiles in Prostate Cancer Under Treatment: Implications for Prognosis and Synergistic Therapy Design.

Cancers·2026

Low incidence of significant hydrogel spacer rectal wall infiltration: results from an experienced high-volume center.

Frontiers in oncology·2025

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer.

Medicina (Kaunas, Lithuania)·2024

Surveillance after Focal Therapy - a Comprehensive Review.

Prostate cancer and prostatic diseases·2024

IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.

NEJM evidence·2024

Comparative effectiveness of apalutamide-, abiraterone-, and enzalutamide-based doublets in mHSPC.

BJU international·2026

Kidney stones composition prediction using artificial intelligence (KiSCAI) study.

BJU international·2026

Sexual satisfaction, sexual function, and orgasm after gender-affirming vaginoplasty and vulvoplasty.

BJU international·2026

Sexual function after prostate cancer surgery or radiotherapy in an international registry.

BJU international·2026

Identifying the ideal candidate for irreversible electroporation in localized prostate cancer: a comprehensive narrative review from the EAU Section of Endourology.

BJU international·2026

The physiology of the upper urinary tract in endourological times - a narrative review.

BJU international·2026

Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort.

European urology oncology·2026

Extracranial Trigeminal Schwannomas: A Systematic Review of Surgical Outcomes, Anatomical Distribution, and the Evidence Gap in Radiotherapy.

Journal of stomatology, oral and maxillofacial surgery·2026

Bilateral sensitization after unilateral trauma is sex- and age-dependent in mice.

The journal of pain·2026

Stroke after cranial radiation in glioma: Phenotypic differences by concurrent bevacizumab exposure.

Clinical neurology and neurosurgery·2026

Time Trends in Cardiac Doses in 10,000 Patients Receiving Curative Thoracic Radiation Therapy Between 2009 and 2020.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026

A Regression Meta-Analysis for Myelopathy in Re-Irradiation of Non-Spinal Cord Tumours.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us